Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines approved by the European Medicines Agency and the US Food and Drug Administration that have been scored and published by ESMO.

ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 135
3 157
2 56
1 24
NEB 4
Curative setting
A 54
C 3
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 39
Endocrine Tumours 21
Gastrointestinal Cancers 76
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 3
Sarcoma 13
Skin Cancers 29
Thoracic Malignancies 86
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 11
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel Neo-adjuvant HER2 overexpressed invasive ductal breast NeoSphere
    Breast Cancer
    		 Early Breast Cancer HER2+ NeoSphere

    C

    PRELIMINARY SCORE

    • pCR

    ADJUSTMENTS

    SCORE

    • F1

      C
    Trastuzumab emtansine (T-DM1) - Lapatinib + capecitabine As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy EMILIA
    Breast Cancer
    		 Breast Cancer HER2+ EMILIA

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo Treatment of patients with HER2-positive metastatic or locally recurrent unresectable BC who have not received previous anti-HER2 therapy or ChT for metastatic disease CLEOPATRA
    Breast Cancer
    		 Breast Cancer HER2+ CLEOPATRA

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Lapatinib Trastuzumab Lapatinib Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR- metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChT EGF104900
    Breast Cancer
    		 Breast Cancer HER2+ HR- EGF104900

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Palbociclib Fulvestrant Fulvestrant + placebo Patients with hormone receptor-positive, HER2-negative locally advanced or MBC who have received prior endocrine therapy (ET) PALOMA-3
    Breast Cancer
    		 Breast Cancer HR+ HER2- PALOMA-3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Palbociclib Letrozole Letrozole + placebo EMA: Palbociclib for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor. FDA: Palbociclib in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. PALOMA-2
    Breast Cancer
    		 Breast Cancer HR+ HER2- PALOMA-2

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Palbociclib Letrozole Letrozole Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor. PALOMA-1/TRIO-18
    Breast Cancer
    		 Breast Cancer HR+ HER2- PALOMA-1/TRIO-18

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Ribociclib Letrozole Letrozole + placebo Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-2
    Breast Cancer
    		 Breast Cancer HR+ HER2- MONALEESA-2

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Lapatinib Capecitabine Capecitabine Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting EGF100151
    Breast Cancer
    		 Breast Cancer HER2+ EGF100151

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Bevacizumab Paclitaxel Paclitaxel First-line treatment of adult patients with metastatic breast cancer E2100
    Breast Cancer
    		 Breast Cancer - E2100

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Everolimus Exemestane Exemestane + placebo Treatment of HR+, HER2- advanced breast cancer, in combination with exemestane, in postmenpausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor BOLERO-2
    Breast Cancer
    		 Breast Cancer HR+ HER2- BOLERO-2

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Eribulin - Treatment of physician's choice As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after ≥1 ChT regimen for advanced disease EMBRACE
    Breast Cancer
    		 Breast Cancer - EMBRACE

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Eribulin - Treatment of physician's choice Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments Study 305 & Study 301 (Pooled analysis)
    Breast Cancer
    		 Breast Cancer HER2- Study 305 & Study 301 (Pooled analysis)

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Panitumumab FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) First-line treatment of patients with wild-type RAS mCRC PRIME
    Gastrointestinal Cancers
    		 Colorectal Cancer RAS-WT PRIME

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Cetuximab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) Treatment of patients with EGFR-expressing, RAS wild-type mCRC CRYSTAL
    Gastrointestinal Cancers
    		 Colorectal Cancer EGFR-expressing RAS-WT CRYSTAL

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Cetuximab - Best supportive care Treatment of patients with EGFR-expressing, RAS wild-type mCRC in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan CO.17
    Gastrointestinal Cancers
    		 Colorectal Cancer KRAS-WT CO.17

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Bevacizumab IFL (irinotecan, leucovorin, fluorouracil) IFL (irinotecan, leucovorin, fluorouracil) + placebo Treatment of patients with metastatic carcinoma of the colon or rectum AVF2107g
    Gastrointestinal Cancers
    		 Colon and Rectal Cancer - AVF2107g

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Panitumumab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) Second-line treatment of patients with wild-type RAS mCRC who have received first-line fluoropyrimidine-based ChT (excluding irinotecan) 20050181 study
    Gastrointestinal Cancers
    		 Colorectal Cancer RAS-WT 20050181 study

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Ramucirumab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) + placebo Treatment of patients with mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine RAISE
    Gastrointestinal Cancers
    		 Colorectal Cancer - RAISE

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Bevacizumab FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil) FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil) Treatment of patients with metastatic carcinoma of the colon or rectum E3200
    Gastrointestinal Cancers
    		 Colorectal Cancer - E3200

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Panitumumab - Best supportive care Treatment of patients with wild-type RAS mCRC after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing ChT regimens Study 20020408
    Gastrointestinal Cancers
    		 Colorectal Cancer RAS-WT Study 20020408

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Oxaliplatine FOLFOXIRI + bevacizumab FOLFIRI + bevacizumab Treatment of patients with metastatic carcinoma of the colon or rectum TRIBE
    Gastrointestinal Cancers
    		 Colon and Rectal Cancer - TRIBE

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Regorafenib - Placebo Treatment of patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based ChT, an anti-VEGF therapy and an anti-EGFR therapy CORRECT
    Gastrointestinal Cancers
    		 Colorectal Cancer - CORRECT

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Aflibercept FOLFIRI FOLFIRI + placebo Metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin containing regimen VELOUR
    Gastrointestinal Cancers
    		 Colorectal Cancer - VELOUR

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Bevacizumab Chemotherapy Chemotherapy Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based ChT for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen ML18147
    Gastrointestinal Cancers
    		 Colon and Rectal Cancer - ML18147

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Epirubicin, 5-FU, Cisplatin + surgery - Surgery Peri-operative resectable gastric or gastroesophageal junction adenocarcinoma MAGIC
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - MAGIC

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU + cisplatin + surgery - Surgery Peri-operative resectable gastric or gastroesophageal junction adenocarcinoma FRE-FNCLCC-94012
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - FRE-FNCLCC-94012

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Ramucirumab Paclitaxel Paclitaxel + placebo Advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine ChT RAINBOW
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - RAINBOW

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Ramucirumab - Placebo Treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine ChT, when treatment in combination with paclitaxel is not appropriate REGARD
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - REGARD

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    FOLFIRINOX - Gemcitabine First-line metastatic pancreatic cancer in patients with good performance status PRODIGE 4/ACCORD 11
    Gastrointestinal Cancers
    		 Pancreatic cancer - PRODIGE 4/ACCORD 11

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.